(Q42483263)

English

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells

scientific article published on January 1990

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

author name string

C Fortis

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

E Ferrero

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

C Besana

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

M Biffi

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

S Heltai

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

L Galli

6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

A Borri

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

A Schoenheit

8

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

C Rugarli

9

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 1990

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

161-166

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review

1 reference

https://api.crossref.org/works/10.1007%2FBF01771451

21 January 2018

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cell growth factor: parameters of production and a quantitative microassay for activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous culture of T cells cytotoxic for autologous human leukaemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 augments natural killer cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strategies for cell-mediated immunotherapy of cancer: killing or help?

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional and morphologic characterization of human T cells continuously grown in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular cloning of human interleukin 2 cDNA and its expression inE. coli

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two types of mouse helper T-cell clone Implications for immune regulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical characterization of lymphocyte regulatory molecules. II. Purification of a class of rat and human lymphokines

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the 2H4 molecule in the activation of suppressor inducer function

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2289209

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01771451

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42483263&oldid=2205434478"